RxDoctor Payments Data

Safwan Jaradeh, MD

Clinical Neurophysiology · Stanford, CANPI 1730130576

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,399 of the $34,032 with a category attached, or 71.7%. 5 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 43.8% of the total. Reporting peaked in 2021 at $13,815 and has fallen 88.1% since, to $1,644 in 2025.

$34,032in general payments, 2019–2025

Across 38 payments — averaging $895.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$15K
  • Akcea Therapeutics, Inc.$11K
  • Takeda Pharmaceuticals U.S.A., Inc.$4K
  • AstraZeneca$4K
  • UCB, Inc.$33
$159,876in research payments, 2019–2025

Across 5 payments — averaging $31,975 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alnylam Pharmaceuticals Inc.$160K

What the payments were for

  • Consulting fees$24,39972%
  • Speaking & faculty fees$6,85020%
  • Travel & lodging$1,6595%
  • Food & beverage$1,0913%
  • Education$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,032 in reported general payments places this provider in the 85th percentile of 49 clinical neurophysiology providers in California.

See all clinical neurophysiology providers in California

Medicare billing

Part B allowed, 2024
$52,747
Medicare patients
231
Services billed
610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5036$128,683
Midodrine Hcl80$3,572
Pyridostigmine Bromide57$1,926
Droxidopa13$1,803
Atomoxetine Hcl12$1,092
Fludrocortisone Acetate26$579
Baclofen25$161
Gabapentin12$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$4,140$128,68336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 49 clinical neurophysiology providers in California.

Other clinical neurophysiology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →